This study is a double-blinded randomised trial to assess the efficacy of a probioticsupplement in alleviating symptoms in people with Long COVID.
240 participants with Long COVID will be randomly assigned to either a probiotic or
placebo group in a 1:1 ratio for twelve weeks. Participants will track symptoms using an
app for three weeks before the study, and for the last three weeks of the treatment.
Participants will answer online questionnaires about their symptoms at 0, 4, 8, and 12
weeks. A subgroup of 60 participants will attend the laboratory for blood tests,
cognitive function tests and gut microbiome analysis at 0 and 12 weeks. This group will
also wear activity trackers for two weeks before the study, and for the final two weeks
of the study.
Dietary Supplement: Probiotic
Probiotic taken daily for 12 weeks.
Dietary Supplement: Placebo
Placebo taken daily for 12 weeks.
Inclusion Criteria: Long COVID defined as National Institute for Health and Care
Excellence (NICE) criteria for Long COVID (Persistent symptoms at least 12 weeks after a
confirmed or suspected Covid-19 infection).
- Exclusion Criteria: Significant co-morbidities - no pre-existing diagnosis of
hypertension, diabetes, cerebrovascular, cardiovascular or peripheral vascular disease,
coagulopathy or haematological disorder or current or recent cancer.
-
Sheffield Hallam University
Sheffield, United Kingdom
Investigator: Caroline Dalton, PhD
Contact: 44-114-225-3695
c.f.dalton@shu.ac.uk
Caroline Dalton, PhD
44-114-225-3695
c.f.dalton@shu.ac.uk
Caroline Dalton, PhD, Principal Investigator
Sheffield Hallam University